Reported Issues: Consumers report: That the supplement did not lead to weight loss or appetite suppression as advertised That the product was marketed using misleading claims about GLP-1 support That they paid for a product that did not provide the promised benefits That the supplements are promoted as alternatives to GLP-1 medications, despite not functioning like prescription GLP-1 drugs That marketing materials imply that these supplements are scientifically and medically proven and reliable, when evidence may be lacking That they would not have purchased the supplements if they had known the claims were not supported by reliable scientific evidence Experiencing adverse side effects such as stomach pain, nausea, or weight gain Why Individuals Should Be Concerned: Potential claims include: Economic loss Safety risk False advertising Product defect Performance vs
Nasal Sprays: Some peptides can be absorbed effectively through the nasal mucosa to achieve systemic effects
Health Canada has approved Zepbound (tirzepatide) as the first medication in Canada indicated for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults living with obesity
They matched these patients to form 3,178 pairs based on sex, weight, age, treatment windows, and other existing medical conditions
The expiration date applies to the unused product stored as labeled
Cleaning up a site as extensively contaminated as Holloman Lake presents unprecedented challenges
